Vir Biotechnology (VIR) Could Be 60% Undervalued On CFO Transition

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Vir Biotechnology (VIR) stock is in focus after Chief Financial Officer Jason O’Byrne decided to step down effective August 3, 2026, with senior finance executive Brent Sabatini appointed as the interim principal financial officer.

See our latest analysis for Vir Biotechnology.

Recent trading reflects this leadership change coming at a time when Vir Biotechnology’s 30 day share price return is down 9.41% and its 90 day share price return is down 13.40%. This is despite a year to date share price return of 45.79% and a 1 year total shareholder return of 72.17%, alongside weaker 3 and 5 year total shareholder returns, which together suggest earlier momentum has cooled after a strong rebound.

If this kind of leadership transition has you thinking about where else growth stories might emerge in healthcare, it could be worth scanning 41 healthcare AI stocks.

With Vir Biotechnology shares recently weaker but sitting far below the average analyst target of US$21.56, the spread between price and estimates is wide. So where might fair value realistically sit now as the valuation details come into focus?

Most Popular Narrative: 60% Undervalued

Vir Biotechnology’s most followed valuation narrative places fair value at about $21.56 per share compared with the last close of $8.66. This indicates a wide gap that hinges on ambitious growth and margin assumptions.

The analysts have a consensus price target of $21.56 for Vir Biotechnology based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $16.0.

Read the complete narrative.

Want to see how this valuation case for Vir Biotechnology is built? The narrative leans on sharp revenue expansion, a step change in profitability, and a premium earnings multiple. The crucial details sit in those forward assumptions, not the current income statement.

Result: Fair Value of $21.56 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this Vir Biotechnology story still hinges on unproven therapies and timely regulatory approvals, so trial setbacks or delays could quickly challenge that case for the shares being 60% undervalued.

Find out about the key risks to this Vir Biotechnology narrative.

Another View on Vir Biotechnology’s Valuation

While analysts frame Vir Biotechnology as about 60% undervalued at a fair value of $21.56, the current P/S ratio of 22.3x tells a different story. It sits above both the US Biotechs industry at 10.8x and the peer average at 20.5x, and also above a fair ratio of 0x. This points to a rich pricing gap that could matter if revenue expectations are not met. Which signal do you trust more when those assumptions are tested?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on Vir Biotechnology split between opportunity and risk, now is a good time to review the full data and pressure test the story for yourself. To understand both sides of the debate, take a closer look at the 1 key reward and 3 important warning signs

Looking for more investment ideas beyond Vir Biotechnology?

If Vir Biotechnology has sharpened your focus on opportunities, do not stop here. The Simply Wall St screener can surface very different types of stocks worth your attention.

Scan for potential mispricing by reviewing companies highlighted in the 55 high quality undervalued stocks and see which ones match your return and risk preferences.

Strengthen your watchlist by focusing on resilience through the 81 resilient stocks with low risk scores, especially if capital preservation sits high on your priority list.

Hunt for potential future standouts by checking the screener containing 20 high quality undiscovered gems before they attract wider attention and become crowded ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include VIR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com